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SUmmAry – docetaxel improved the outcome of patients with mCSPC and became standard 
of care after ChAArted, StAmPede arm C and getUg-AfU 15 clinical trials and after 
subsequent meta-analysis. Patients with high-volume (ChAArted definition) and high-risk 
(lAtitUde definition) disease, who have good performance status and are fit for chemotherapy, 
seem to benefit the most from addition of docetaxel to the androgen deprivation therapy. results from 
titAn trial with apalutamide showed the activity in the same setting. however, predictive biomark-
ers are still lacking. We have direct evidence of overall survival benefit from abiraterone, apalutamide 
and enzalutamide for patients with high-volume disease who are not fit for chemotherapy, as well as 
for patients with low-volume disease. Clinical trials will show is there place for triple therapy in clini-
cal practice. before obtaining the results of new clinical trial results, physicians should base their treat-
ment decision on risks and benefits of each current approach and consider the patient´s other health 
issues such as access, costs, patient and patient´s preferences.
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Introduction
Although androgen-deprivation therapy (Adt) is 
still the backbone of treatment, addition of docetaxel, 
abiraterone acetate, enzalutamide or apalutamide has 
improved the outcome for patients with mCSPC and 
has become a standard of care. to date, no head-to-
head comparisons between current treatment options 
are available1-5.
Evidence on docetaxel in treatment of mCSPC
Adt plus docetaxel for six cycles is considered a 
standard of care for high-volume mCSPC based on 
ChAArted, StAmPede arm C and getUg-
AfU 15 clinical trials. ChAArted and StAm-
Pede arm C demonstrated that up-front docetaxel 
plus Adt improves overall survival (oS) of patients 
with mCSPC. in ChAArted clinical trial, benefit 
from Adt plus docetaxel in terms of median oS was 
51 months and with Adt alone it was 34 months; 
hr 0.63; 95% Ci, 0.50–0.79. Similar to ChAArt-
ed, Adt plus docetaxel significantly improved me-
dian oS compared with Adt alone in StAmPede 
arm C (81 months vs. 71.3 months; hr 0.78; 95% Ci, 
0.66–0.93). Subsequent meta-analysis established 
Adt plus docetaxel as a standard of care for fit pa-
tients with high-volume or high-risk mCSPC.
Predictive biomarkers are needed to select patients 
for optimal treatment. Until those are identified, Adt 
plus docetaxel may be considered for patients with 
high-volume disease mCSPC (presence of visceral 
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metastases or ≥4 bone lesions with ≥1 beyond the ver-
tebral bodies and pelvis, according to ChAArted 
definition) or high-risk disease (presence of at least 
two of three criteria [of a gleason score of ≥8, at least 
three bone lesions and the presence of visceral metas-
tasis], according to the lAtitUde definition), who 
have a good performance status, desire shorter total 
treatment time or have concerns about prescription 
drug costs.
Position of docetaxel in comparison to other, 
newer androgen receptor inhibitor
for patients with high-volume disease and not fit 
for chemotherapy as well as for patients with low-vol-
ume disease, we have direct evidence of overall  survival 
benefit from abiraterone, apalutamide and enzalu-
tamide added to testosterone suppression. There is a 
possibility that with a lower tumor volume, there may 
be fewer hormone-insensitive clones that would be 
unresponsive to an androgen receptor signaling/tar-
geted inhibitor, so we can conclude that with high tu-
mor volume it would be beneficial to combine chemo-
therapy with androgen receptor signaling/targeted in-
hibitor. it is undeniable that some men with high-vol-
ume disease might benefit from triple therapy with 
androgen-deprivation therapy, docetaxel and an an-
drogen-receptor inhibitor, which may further delay 
symptomatic and radiographic disease progression or 
death. but, in 2019, there has been no clear overall sur-
vival benefit from docetaxel plus enzalutamide (en-
ZAmet, ArCheS clinical trials; hr = 0.90, 95% 
Ci = 0.62–1.31) or apalutamide (titAn clinical trial; 
hr = 1.27, 95% Ci = 0.52–3.09), although these con-
fidence intervals are wide and do not exclude a clini-
cally meaningful survival benefit. overall survival re-
sults of the titAn trial were surprising, but another 
revealing aspect of the titAn trial is that survival 
benefit appeared to be at least as good in patients with 
low-volume disease as in those with high-volume dis-
ease, and regardless of whether the patient was newly 
diagnosed or had disease progression from a localized 
to a metastatic state. it is important to note that those 
with combined visceral and bone metastases do not do 
as well. further follow-up and meta-analyses, as well 
as results from the ArASenS clinical trial (darolu-
tamide with docetaxel), can address questions about 
combination therapy.
Discussion
The ultimate choice for an individual patient de-
pends on the physician detailing risks and benefits of 
each approach and considering patient´s other health 
issues such as access, costs and patient´s preference. 
We need to bear in mind that previous exposure to 
docetaxel or an ArtA has different clinical and bio-
logical implications because, as they were administered 
in an early disease phase, their activity is likely to be 
different from that observed in mCrPC patients.
Androgen-deprivation therapy alone appears to be 
suboptimal care in 2019 and is rarely used in our daily 
clinical practice for patients with limited life expec-
tancy (<3 years) due to competing comorbid illness, 
and for patients with severe dementia who may be 
overtreated if given combination therapy. for those 
who decide to start androgen-deprivation therapy 
alone as systemic therapy in metastatic castration-sen-
sitive prostate cancer patients with better perspective, 
the guide would be to observe PSA response closely 
and consider additional treatment if PSA levels do not 
decline to less than 0.2 ng/ml after 6 to 8 months. 
Such patients are most likely to have early progression 
to metastatic castration-resistant prostate cancer and 
shortened survival with androgen-deprivation therapy 
alone. for patients who do not have high-volume or 
high-risk disease, there will still be a dilemma about 
upfront use of apalutamide or enzalutamide or wheth-
er subsequent therapy should be applied if they devel-
op metastatic castration-resistant prostate cancer.
Conclusion
Clinicians’ decisions are usually supported by the 
type of clinical presentation (symptomatic vs mild or 
asymptomatic disease), the site of metastases (visceral 
vs nonvisceral), the presence of significant co-morbid-
ities, the safety of the drug and its potential interac-
tions with other medications. docetaxel is a good 
therapy option for the fit mCSPC patients, especially 
in countries with limited resources.
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Sažetak
U KoJih boleSniKA PrimiJeniti hormonSKU terAPiJU + doCetAKSel
M. Gamulin, M. Bebek i M. Gnjidic
Uvođenje kemoterapije docetakselom je dovelo do unaprijeđenja ishoda liječenja u bolesnika s metastatskim senzitivnim 
rakom prostate te je dodatak docetaksela postao standard liječenja što je temeljeno na rezultatima studija ChAArted, 
StAmPede, grane C i getUg-AfU 15 studiji te nakon toga učinjene meta analize. bolesnici s visokim volumenom 
bolesti (definicija po ChAArted studiji) i visokog rizika (definicija prema lAtitUtde studiji), koji imaju dobar per-
formance status i koji su pogodni za kemoterapiju, imaju najviše koristi od dodatka docetaksela androgenoj deprivacijskoj 
terapiji. rezultati titAn studije su pokazali aktivnosti apalutamida u istoj indikaciji. ipak, prediktivni biomarkeri još uvijek 
nedostaju. Postoje jasni dokazi o koristi u ukupnom preživljenju od abiraterona, apalutamida i enzalutamida u bolesnika s 
bolesti visokog volumena koji nisu pogodni za kemoterapiju, kao i za bolesnike s bolesti niskog volumena. Kliničke studije će 
pokazati mjesto za trostruku terapiju u kliničkoj praksi. Prije objave rezultata novih kliničkih studija, liječnici trebaju teme-
ljiti svoje odluke na temelju procjene rizika i koristi svakog trenutnog pristupa i razmotriti druge parametre poput troškova 
liječenja, dostupnosti skrbi te preferencije bolesnika.
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